According to the Insight database, between June 23 and June 25, AstraZeneca intensively initiated six Phase III clinical trials for Elecoglipron, with indications covering obesity and type 2 diabetes. Elecoglipron (development codes: ECC5004 / AZD5004) is a once-daily, low-dose, small-molecule…
On June 16, the official website of the Drug Clinical Trial Registration and Information Disclosure Platform showed that Qilu Pharmaceutical has initiated an open-label, multicenter Phase I clinical study (Registration No.: CTR20262372) to evaluate the safety, tolerability, pharmacokinetics, and preliminary…
On June 15, the Drug Clinical Trial Registration and Information Disclosure Platform showed that The United Laboratories (TUL) has registered a Phase III clinical trial (overweight/obesity) for UBT251 Injection. This is a randomized, double-blind, parallel, placebo-controlled Phase III study designed…
On June 11, the U.S. clinical trials registry website showed that Biohaven has initiated the first Phase III clinical trial (BHV1400-301) for BHV-1400, its next-generation degrader. The study is a randomized, multicenter, double-blind, placebo-controlled clinical trial (n=420) designed to evaluate…
On May 26, 2026, Henlius (2696.HK) announced that the first patient has been dosed in China in the randomized, double-blind, multicenter, parallel-controlled Phase II/III clinical study evaluating pimurutamab (HLX07), the Company’s proprietary recombinant anti-EGFR monoclonal antibody, in combination with H药 汉斯状®…
On June 4 local time, the ClinicalTrials website showed that Hengrui Medicine registered a Phase III clinical trial of HRS-7535 for the treatment of chronic kidney disease (CKD) . This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group Phase III study designed…
Roche’s Obinutuzumab Injection (Brand Name: Gazyvaro®/Gazyva®) has been granted priority review by the CDE for the treatment of primary membranous nephropathy (pMN). In February of this year, Roche announced that the study met its primary endpoint: the proportion of patients…
On June 4 local time, the ClinicalTrials website showed that SystImmune, a wholly-owned subsidiary of Baili Tianheng, registered a Phase III clinical trial of BL-M14D1 in combination with Tecentriq for the first-line treatment of extensive-stage small cell lung cancer. According…
This morning, Qihan Biotech reported preliminary positive clinical data for its in vivo CAR-T therapy. Qihan Biotech did not disclose specific information about its in vivo CAR-T pipeline. It is only known that the company’s first in vivo CAR-T program…
On May 20, CDE issues an announcement that Insilico Medicine’s new drug clinical trial application for ISM8969/HT-001 tablets has been accepted for review. The drug received an FDA clinical trial approval in January this year. The acceptance of the domestic…